Adagrasib, a KRAS G12C inhibitor, was granted FDA approval in 2022 for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose disease had progressed following one prior therapy.3 Here, KRAS is linked to non-small cell lung carcinoma.